Ticker brief
VSTM
last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
38
authors 14d
22
crowd 14d
+1.5σ
No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.
Sentiment — last 14 days
daily mean sentiment, 2026-10-04 → 2026-10-16 · now +0.42 (−1 bearish … +1 bullish)
Who spoke22
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @PersimmonTI | A | +0.79 | 5 | +0.56 |
| @BiopharmIQ | B | · | 4 | +0.14 |
| @zohmbastic | C | -2.94 | 3 | +0.25 |
| @PrismMarketView | C | · | 2 | +0.25 |
| @PrismDM | A | -2.76 | 2 | +0.23 |
| @Briefingcom | B | -2.26 | 2 | +0.40 |
| @joinlegendsonly | C | +1.03 | 2 | +0.55 |
| @AlertsAndNews | C | -3.92 | 2 | +0.38 |
| @bioinvestor24 | A | -0.87 | 2 | +0.50 |
| @Tickeron | C | +1.53 | 2 | +0.58 |
| @BioStocks | C | -1.77 | 1 | +0.60 |
| @Maximus_Holla | C | -2.13 | 1 | +0.10 |
| @theflynews | C | · | 1 | +0.10 |
| @kkernttb | C | -0.95 | 1 | +0.00 |
| @tenet_research | C | -1.23 | 1 | +0.00 |
| @TENETTRADEGROUP | C | -0.65 | 1 | +0.00 |
| @OpenOutcrier | C | · | 1 | +0.25 |
| @OzmosiHealth | C | · | 1 | +0.60 |
| @BAlmohsin1 | C | -0.24 | 1 | +0.70 |
| @OptionsFlowBoss | C | · | 1 | +0.35 |
| @AponiaAnalytics | B | -1.06 | 1 | +0.45 |
| @semodough | C | -1.06 | 1 | +0.60 |
Recent signals30of 38 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-10-16 | @zohmbastic | +0.25 | Reports VSTM moving from red to green intraday. | · | tweet ↗ |
| 2026-10-16 | @zohmbastic | +0.40 | Mizuho raised VSTM's target to $14 from $13, retained Outperform and cited encouraging clinical data. | · | tweet ↗ |
| 2026-10-16 | @semodough | +0.60 | Cantor views VSTM as a leading way to gain exposure to RAS inhibitors, with about 13 catalysts. | · | tweet ↗ |
| 2026-10-15 | @bioinvestor24 | +0.50 | Compares oncology response and toxicity data, praising VSTM efficacy while flagging vomiting and liver-enzyme risks. | · | tweet ↗ |
| 2026-10-15 | @PersimmonTI | +0.65 | Author says the VSTM data speak loudly, implying a favorable interpretation. | · | tweet ↗ |
| 2026-10-15 | @zohmbastic | +0.10 | Sets an alert around the VSTM 9 price level without a stated trade entry. | · | tweet ↗ |
| 2026-10-15 | @Tickeron | +0.60 | Favors VSTM's clinical and revenue momentum over ZBAO's listing and price risks. | · | tweet ↗ |
| 2026-10-15 | @Tickeron | +0.55 | Favors VSTM's approved product and funding over HUBC's listing and liquidity risks. | · | tweet ↗ |
| 2026-10-14 | @AlertsAndNews | +0.50 | Recaps 23 targets hit across completed stock and options alerts. | · | tweet ↗ |
| 2026-10-14 | @AponiaAnalytics | +0.45 | Reports encouraging but early response rates for VSTM's VS-7375 in pancreatic cancer. | · | tweet ↗ |
| 2026-10-14 | @OptionsFlowBoss | +0.35 | Reports unusual bullish options-volume multiples halfway through the session. | · | tweet ↗ |
| 2026-10-14 | @BiopharmIQ | +0.20 | Reports positive early response data and a concurrent $250 million equity offering. | · | tweet ↗ |
| 2026-10-14 | @BiopharmIQ | +0.35 | Lists opening price moves tied to company catalysts; output is capped at the first six tickers. | · | tweet ↗ |
| 2026-10-14 | @bioinvestor24 | +0.50 | Views VSTM data as decent and cites MRK's payment for a similar preclinical asset. | · | tweet ↗ |
| 2026-10-14 | @PersimmonTI | +0.20 | Hints that VSTM's conference call contained something important but withholds the substance and direction | · | tweet ↗ |
| 2026-10-14 | @PrismDM | +0.05 | Verastem reported positive response data, priced a $250M offering, and named a new CEO. | · | tweet ↗ |
| 2026-10-14 | @PrismMarketView | +0.10 | Reports clinical response data, a $250M raise, and a new CEO. | · | tweet ↗ |
| 2026-10-14 | @joinlegendsonly | +0.70 | Reports that VSTM already hit all upside targets and continues higher. | · | tweet ↗ |
| 2026-10-14 | @BAlmohsin1 | +0.70 | Recaps a completed VSTM plan producing a stated 10% gain. | · | tweet ↗ |
| 2026-10-14 | @OzmosiHealth | +0.60 | VS-7375 showed a 50% confirmed response rate and complete responses in advanced KRAS G12D cancers. | · | tweet ↗ |
| 2026-10-14 | @AlertsAndNews | +0.25 | Notes a substantial influx of call-option activity in VSTM. | · | tweet ↗ |
| 2026-10-14 | @OpenOutcrier | +0.25 | Verastem reported early trial data for VS-7375 across several cancer types. | · | tweet ↗ |
| 2026-10-14 | @joinlegendsonly | +0.40 | Provides VSTM premarket support and conditional upside targets. | · | tweet ↗ |
| 2026-10-14 | @TENETTRADEGROUP | +0.00 | Premarket-movers list identifies active stocks without expressing direction. | · | tweet ↗ |
| 2026-10-14 | @tenet_research | +0.00 | Lists premarket movers without providing individual direction or figures in the text. | · | tweet ↗ |
| 2026-10-14 | @Briefingcom | +0.50 | Reports 50% confirmed response for VS-7375 and FDA alignment on a Phase 3 pancreatic-cancer trial design. | · | tweet ↗ |
| 2026-10-14 | @kkernttb | +0.00 | Publishes an updated multi-name watchlist without entries or directional stances. | · | tweet ↗ |
| 2026-10-14 | @Briefingcom | +0.30 | Lists leading premarket gaps; ticker cap retains the five gainers and largest decliner. | · | tweet ↗ |
| 2026-10-14 | @theflynews | +0.10 | Verastem appointed Michel Bailey CEO effective January 1. | · | tweet ↗ |
| 2026-10-14 | @PersimmonTI | +0.75 | Strongly endorses VSTM and its VS-7375 program. | · | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.